文献速递胸部肿瘤放疗放疗物理与技术

局部晚期肺癌的肺部磁共振引导在线自适应放疗:PUMA试验

Pulmonary magnetic resonance-guided online adaptive radiotherapy of locally advanced: the PUMA trial.
PubMed 文献 · Radiat Oncol · 2023-05-04

PUMA是一项前瞻性、多中心I期试验,计划在3家德国大学医院入组30例IIIA-C期局部晚期非小细胞肺癌患者,评估MR引导在线自适应放疗联合同步化疗的临床可行性。主要终点为成功完成在线自适应分次的次数和在线治疗时间。

要点

  • PUMA试验拟入组30例IIIA-C期局部晚期非小细胞肺癌患者,接受MR引导在线自适应放疗联合同步化疗。
  • 常规分割放疗联合等毒性剂量递增至70 Gy,在线计划自适应每周一次或解剖明显变化时进行。
  • 主要终点为成功完成在线自适应分次的次数和在线治疗时间;主要次要终点包括自适应频率、毒性、局部肿瘤控制、无进展生存和总生存。

核心结论

  • PUMA试验旨在证明MR引导在线自适应放疗治疗局部晚期非小细胞肺癌的临床可行性。
  • 若试验成功,后续将开展II期临床试验进一步研究该方法的临床获益。

研究设计与样本

  • 前瞻性、多中心I期试验,计划在3家德国大学医院入组30例IIIA-C期局部晚期非小细胞肺癌患者。
  • 患者接受两种MR-linac系统(MRIdian Linac®,ViewRay公司;Elekta Unity®,Elekta公司)的MR引导在线自适应放疗,联合同步化疗。
  • 采用常规分割放疗联合等毒性剂量递增至70 Gy;在线计划自适应每周一次或解剖明显变化时进行。
  • 治疗后通过胸部CT和MR影像随访24个月。

主要发现

  • 主要终点为成功完成在线自适应分次的次数和在线治疗时间。
  • 主要次要终点包括自适应频率、毒性、局部肿瘤控制、无进展生存和总生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with locally-advanced non-small-cell lung cancer (LA-NSCLC) are often ineligible for surgery, so that definitive chemoradiotherapy (CRT) represents the treatment of choice. Nevertheless, long-term tumor control is often not achieved. Intensification of radiotherapy (RT) to improve locoregional tumor control is limited by the detrimental effect of higher radiation exposure of thoracic organs-at-risk (OAR). This narrow therapeutic ratio may be expanded by exploiting the advantages of magnetic resonance (MR) linear accelerators, mainly the online adaptation of the treatment plan to the current anatomy based on daily acquired MR images. However, MR-guidance is both labor-intensive and increases treatment times, which raises the question of its clinical feasibility to treat LA-NSCLC. Therefore, the PUMA trial was designed as a prospective, multicenter phase I trial to demonstrate the clinical feasibility of MR-guided online adaptive RT in LA-NSCLC. METHODS: Thirty patients with LA-NSCLC in stage III A-C will be accrued at three German university hospitals to receive MR-guided online adaptive RT at two different MR-linac systems (MRIdian Linac®, View Ray Inc. and Elekta Unity®, Elekta AB) with concurrent chemotherapy. Conventionally fractioned RT with isotoxic dose escalation up to 70 Gy is applied. Online plan adaptation is performed once weekly or in case of major anatomical changes. Patients are followed-up by thoracic CT- and MR-imaging for 24 months after treatment. The primary endpoint is twofold: (1) successfully completed online adapted fractions, (2) on-table time. Main secondary endpoints include adaptation frequency, toxicity, local tumor control, progression-free and overall survival. DISCUSSION: PUMA aims to demonstrate the clinical feasibility of MR-guided online adaptive RT of LA-NSCLC. If successful, PUMA will be followed by a clinical phase II trial that further investigates the clinical benefits of this approach. Moreover, PUMA is part of a large multidisciplinary project to develop MR-guidance techniques. TRIAL REGISTRATION: ClinicalTrials.gov: NCT05237453 .

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Regnery S, de Colle C, Eze C, et al. Pulmonary magnetic resonance-guided online adaptive radiotherapy of locally advanced: the PUMA trial. Radiat Oncol. 2023. PMID: 37143154. doi:10.1186/s13014-023-02258-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。